Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. [electronic resource]
Producer: 20100812Description: 180-2 p. digitalISSN:- 1528-0020
- Aged, 80 and over
- Anabolic Agents -- therapeutic use
- Anemia, Refractory -- drug therapy
- Anemia, Sideroblastic -- drug therapy
- Antineoplastic Agents -- therapeutic use
- Erythropoietin -- therapeutic use
- Humans
- Hypertension, Pulmonary -- complications
- Janus Kinase 2 -- genetics
- Lenalidomide
- Male
- Middle Aged
- Mutation
- Pulmonary Embolism -- complications
- Pyridoxine -- therapeutic use
- Reverse Transcriptase Polymerase Chain Reaction
- Thalidomide -- analogs & derivatives
- Thrombocytosis -- drug therapy
- Vitamin B Complex -- therapeutic use
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.